Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM082 in wet AMD Phase II single-arm study
CTR20181510Phase 2Active
- Sponsor
- Cananji Pharmaceutical Technology
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorolanib in exudative macular degeneration, sponsored by Cananji Pharmaceutical Technology. Started Oct 2018; status: active.
02
Drugs
vorolanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20181510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181510.